Kiniksa Pharmaceuticals: $35.8M Assets vs $41.9M Liabilities in 2024

Ticker: KNSA · Form: 10-K · Filed: 2025-02-25T00:00:00.000Z

Sentiment: bearish

Topics: financials, balance-sheet, pharmaceuticals

TL;DR

Kiniksa ended 2024 with more liabilities ($41.9M) than assets ($35.8M).

AI Summary

Kiniksa Pharmaceuticals International, plc filed its 2024 10-K on February 25, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, operating in the pharmaceutical preparations sector, had total assets of $35.8 million and total liabilities of $41.9 million as of December 31, 2024. This indicates a net liability position for the company at year-end.

Why It Matters

This filing provides a snapshot of Kiniksa Pharmaceuticals' financial health, showing a net liability position which could impact its ability to fund operations or future growth.

Risk Assessment

Risk Level: medium — The company has more liabilities than assets, which could indicate financial strain or a need for additional financing.

Key Numbers

Key Players & Entities

FAQ

What were Kiniksa Pharmaceuticals' total assets and liabilities as of December 31, 2024?

As of December 31, 2024, Kiniksa Pharmaceuticals reported total assets of $35,781,373 and total liabilities of $41,881,319.

When did Kiniksa Pharmaceuticals file its 2024 10-K report?

Kiniksa Pharmaceuticals filed its 2024 10-K report on February 25, 2025.

What is the Standard Industrial Classification (SIC) code for Kiniksa Pharmaceuticals?

The SIC code for Kiniksa Pharmaceuticals is 2834, which corresponds to Pharmaceutical Preparations.

What was the retained earnings balance for Kiniksa Pharmaceuticals at the end of fiscal year 2024?

The filing indicates a retained earnings balance for 2024-12-31, but the specific dollar amount is not provided in the excerpt.

What is the company's former name and when was the name change effective?

The company's former name was Kiniksa Pharmaceuticals, Ltd., and the name change to Kiniksa Pharmaceuticals International, plc was effective on 2018-02-05.

From the Filing

0001558370-25-001505.txt : 20250225 0001558370-25-001505.hdr.sgml : 20250225 20250225161546 ACCESSION NUMBER: 0001558370-25-001505 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 108 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250225 DATE AS OF CHANGE: 20250225 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Kiniksa Pharmaceuticals International, plc CENTRAL INDEX KEY: 0001730430 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38492 FILM NUMBER: 25663435 BUSINESS ADDRESS: STREET 1: 23 OLD BOND STREET, FLOOR 3 CITY: LONDON STATE: X0 ZIP: WIS 4PZ BUSINESS PHONE: 7814319100 MAIL ADDRESS: STREET 1: 23 OLD BOND STREET, FLOOR 3 CITY: LONDON STATE: X0 ZIP: WIS 4PZ FORMER COMPANY: FORMER CONFORMED NAME: Kiniksa Pharmaceuticals, Ltd. DATE OF NAME CHANGE: 20180205 10-K 1 knsa-20241231x10k.htm 10-K Kiniksa Pharmaceuticals International, plc_December 31, 2024 0001730430 --12-31 2024 FY false 35781373 41881319 1795158 1795158 1795158 16826468 12781964 16057618 16057618 P4Y 0 0 0 0 P48M 0001730430 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001730430 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001730430 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001730430 us-gaap:RetainedEarningsMember 2024-12-31 0001730430 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001730430 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001730430 us-gaap:RetainedEarningsMember 2023-12-31 0001730430 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001730430 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001730430 us-gaap:RetainedEarningsMember 2022-12-31 0001730430 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001730430 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001730430 us-gaap:RetainedEarningsMember 2021-12-31 0001730430 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001730430 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001730430 knsa:KiniksaUkMember us-gaap:CommonClassAMember 2024-06-30 0001730430 knsa:KiniksaBermudaMember us-gaap:ConvertiblePreferredStockMember 2024-06-30 0001730430 knsa:KiniksaBermudaMember us-gaap:CommonClassAMember 2024-06-30 0001730430 knsa:RestrictedStockUnitsRsuPerformanceBasedAwardTwoMember 2021-01-01 2021-12-31 0001730430 knsa:RestrictedStockUnitsRsuPerformanceBasedAwardOneMember 2021-01-01 2021-12-31 0001730430 knsa:EquityIncentivePlan2015Member us-gaap:CommonClassAMember 2024-12-31 0001730430 us-gaap:EmployeeStockOptionMember 2023-12-31 0001730430 knsa:IncentiveAwardPlan2018Member us-gaap:CommonClassAMember 2024-12-31 0001730430 knsa:EmployeeSharePurchasePlan2018Member us-gaap:CommonClassAMember 2024-12-31 0001730430 knsa:IncentiveAwardPlan2018Member us-gaap:CommonClassAMember 2018-05-31 0001730430 knsa:EmployeeSharePurchasePlan2018Member us-gaap:CommonClassAMember 2018-05-31 0001730430 knsa:EmployeeSharePurchasePlan2018Member us-gaap:CommonClassAMember 2025-01-01 2025-01-01 0001730430 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2024-01-01 2024-12-31 0001730430 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2023-01-01 2023-12-31 0001730430 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2022-01-01 2022-12-31 0001730430 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001730430 knsa:RestrictedStockUnitsRsuTimeBasedMember 2024-01-01 2024-12-31 0001730430 srt:MinimumMember us-gaap:EmployeeStockOptionMember knsa:EquityIncentivePlan2015Member 2024-01-01 2024-12-31 0001730430 knsa:CollaborationMember knsa:TerritoryLicenseMavrilimumabMember 2024-01-01 2024-12-31 0001730430 knsa:CollaborationMember knsa:TerritoryLicenseArcalystMember 2024-01-01 2024-12-31 0001730430 us-gaap:ProductMember 2024-01-01 2024-12-31 0001730430

View on Read The Filing